Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802)

Autor:	Salvatore Pisconti, D. Rizzi, Evaristo Maiello, Tiziana Latiano, Antonio Rinaldi, Massimo Di Maio, Antonio Febbraro, Roberto Bordonaro, Saverio Cinieri, Giuseppe Colucci, Gabriele Di Maggio, Francesco Giuliani, Stefano Cordio, Michele Aieta
Rok vydání:	2018
Předmět:	Oncology Cancer Research medicine.medical_specialty Bevacizumab Colorectal cancer business.industry Phases of clinical research medicine.disease Oxaliplatin First line treatment Capecitabine Internal medicine medicine business medicine.drug
Zdroj:	Journal of Clinical Oncology. 36:3542-3542
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.3542
Popis:	3542Background: B plus bi-weekly FOLFOX4 or three-weekly XELOX represents a standard 1-line therapy for mCRC pts. In our previous phase II study (Fedele P et al, ASCO 2009) we demonstrated a simila...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7685538b648779087df7c4803c81f89e https://doi.org/10.1200/jco.2018.36.15_suppl.3542 Zobrazit plný text záznamu